BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting Fabry Drug

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 29 Oct, 19:39 UTC

BioMarin gains rights to a Fabry disease enzyme replacement therapy with potential dosing advantages over products from Sanofi and Chiesi Group. BioMarin’s new clinical-stage asset could reach patients ineligible for the Fabry drug that came with its Amicus Therapeutics acquisition earlier this…